- About
- PsychU For You
- Topics
- Events
- Content
Trace Amine-Associated Receptor 1 (TAAR1): A Potential New Target For The Treatment Of Schizophrenia
Thank You For Attending Today’s Webinar
Please tell us what you thought about today’s presentation by taking the survey below:
About This Event
Trace Amine-Associated Receptor 1 (TAAR1): A Potential New Target For The Treatment Of Schizophrenia
This is a Virtual Event for PsychU members in Delaware, Maryland, New Jersey and Pennsylvania.
Trace amines and trace amine-associated receptors (TAAR) are found throughout the brain and peripheral tissues and have modulating effects on neurotransmitters including dopamine, glutamate, and serotonin.1,2 The speaker(s) will discuss what are some of the potential effects of TAAR1 on neurotransmitter signaling related to schizophrenia and some of the preclinical data, as well as share the potential role of TAAR1 beyond schizophrenia.
Objectives:
- Summarize the Unmet Needs of Schizophrenia as it Relates to Neural Circuitry
- Introduction to Trace Amines (TA) and Trace Amine-Associated Receptors (TAARs) and Their Potential Relationship to Schizophrenia
- Discuss Potential Modulating Effects of TAAR1 on Neurotransmitter Signaling Associated with Schizophrenia Pathophysiology
Salvatore G. Savatta, MD
Chair of Psychiatry, Trinitas Regional Medical Center, Elizabeth, NJ
MoreDr. Salvatore G. Savatta received his Bachelor of Arts degree in Economics from New York University, graduated from New York University School of Medicine in 2001 and completed his M.S. in Biostatistics Clinical Research Methods at Columbia University’s Mailman School of Public Health in 2005. Dr. Savatta has previously served as Director of Inpatient Psychiatry at New York Methodist Hospital, Medical Director of TMS Centers of America and both Deputy Chair and Interim Chair of Psychiatry at Trinitas Regional Medical Center. He presently serves as Chair of Psychiatry at Trinitas and has done so since May of 2020. Dr. Savatta completed his Psychiatry Residency at St. Vincent’s Catholic Medical Center and completed a Public Service Psychiatry Fellowship and a Forensic Psychiatry Fellowship at the University of Pittsburgh Medical Center – Western Psychiatric Institute and Clinic. Dr. Savatta is Board Certified in both Adult Psychiatry and Forensic Psychiatry. He has tailored his clinical practice to focus on “difficult to treat” depression, and often includes the implementation of Neuromodulation techniques such as TMS, Esketamine, and Electroconvulsive Therapy (ECT) when clinically appropriate.
Mark Tacelosky, PharmD (OPDC)
Senior Medical Science Liaison
Speaker Salvatore G. Savatta, MD is a paid consultant for Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC)
Speaker Mark Tacelosky, PharmD is an employee of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC)Registration
- PsychU For You
